

Novel health care strategies for melanoma in children, adolescents and young adults







#### FOLLOW US & STAY UPDATED

www.melcaya.eu

MELCAYA

Service and the service of the servi

♥ @MELCAYA\_EU

MELCAYAeu

# PROJECT BACKGROUND

Melanoma in children, adolescents and young adults (CAYA) is understudied and lacking in adequate preventive, diagnostic as well as therapeutic strategies.

The incidence of melanoma is reported to be about 1.3-1.6 per million in children under 15 years and 15 per million in 15-19 years old, with increasing incidence in adolescents by 4.1% annually since 1997. Additionally, melanoma is among the most frequent solid tumors diagnosed in young adults, with a European incidence of 6.6 per 100,000 and a mortality of 4 per million. Little is known about the interaction between genetic and environmental factors associated with melanoma risk in this context or in the progression from benign nevus to melanoma. Furthermore, lower sensitivity than in adults results in late diagnosis with poorer outcomes, when CAYA patients, particularly the children, could show a 90% 10-year survival rate from stage I/II disease. Thus, melanomas in CAYA represent a medical challenge.

## PROJECT IMPACTS



 $\ensuremath{\text{\textbf{IDENTIFY}}}$  environmental and genetic risk factors for melanoma in CAYA.

**ESTABLISH** molecular profiles of progression from benign congenital nevi to melanoma.



FACILIATE and promote better international collaboration, standards, and melanoma taxonomy.



**EVALUATE** the clinical efficacy and safety of anti-PD1 antibodies in CAYA melanoma patients.



**DEVELOP** an Al-based diagnostic tool to distinguish the images of melanomas from images of nevi or other benign pigmented skin lesions.



**CONDUCT** rapid and non-invasive tools for risk and prognosis of melanoma in CAYA.



**DESIGN** health care system strategies on prevention and diagnosis of melanoma.



**ENSURE** patient research engagement and education throughout the project and its implementation.



### **PROJECT FACTS**

**Duration** 12/2022 to 11/2026

Programme Horizon Europe

HORIZON-MISS-2021-CANCER-02 Research & Innovation Action

**Reference** 101096667

#### Coordinator

AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE – CLINIC FOUNDATION FOR BIOMEDICAL RESEARCH

FOLLOW US & FIND OUT MORE ABOUT OUR LATEST DEVELOPMENTS



Funded by the European Union. Views and opinions sepressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

